Source: International Congress 2019 – Biomarkers of idiopathic interstitial pneumonia
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
T. Yoshikawa (Sapporo, Japan), M. Otsuka (Sapporo, Japan), K. Ikeda (Sapporo, Japan), Y. Mori (Sapporo, Japan), Y. Umeda (Sapporo, Japan), H. Nishikiori (Sapporo, Japan), S. Miyajima (Sapporo, Japan), M. Takahashi (Sapporo, Japan), K. Kuronuma (Sapporo, Japan), H. Chiba (Sapporo, Japan), H. Takahashi (Sapporo, Japan). Change in serum surfactant protein (SP)-A, SP-D and KL-6 predict the therapeutic effect of antifibrotic drugs in IPF.. 4704

Member's Comments

No comment yet.

Related content which might interest you: Serum surfactant protein D (SP-D) is a lung derived biomarker for COPD that is responsive to treatment with oral corticosteroids Source: Annual Congress 2008 - Biomarkers and disease assessment in COPD Year: 2008 Plasma surfactant protein D (SP-D) and nutritive status in patients with COPD Source: Annual Congress 2013 –COPD treatment and others Year: 2013 Human napsin a is a useful serum marker of interstitial lung disease, compared to KL-6, and surfactant protein-D Source: Annual Congress 2009 - Bronchoalveolar lavage and phenotyping in diffuse parenchymal lung disease Year: 2009 Serum concentrations of KL-6 in patients with IPF and lung cancer and serial measurements of KL-6 in IPF patients treated with antifibrotic therapy Source: Virtual Congress 2021 – Biomarkers and e-health in idiopathic interstitial pneumonia Year: 2021 Comparative study of CC16, KL-6 and SP-D as serum markers in sarcoid patients Source: Eur Respir J 2002; 20: Suppl. 38, 173s Year: 2002 Surfactant protein D as a potential serum marker of pulmonary emphysema Source: Annual Congress 2011 - Smoking-related disorders and smoking prevention Year: 2011 The effect of a novel anti-inflammatory agent (ODSH) on C-reactive protein in patients with an acute exacerbation of COPD Source: Annual Congress 2009 - Acute lung injury and biomarkers Year: 2009 Serum KL-6, SP-D and MMP-2 as diagnostic biomarkers in asbestosis and silicosis Source: International Congress 2017 – Silicosis has not gone away Year: 2017 Serum surfactant protein D predicts the outcome of patients with idiopathic pulmonary fibrosis treated with pirfenidone Source: International Congress 2017 – IPF: from the bench to the bedside Year: 2017 Plasma biomarker assay and the immuno-modulatory effect of erythromycin in COPD Source: Annual Congress 2009 - Biomarkers, comorbidities and prognosis of COPD Year: 2009 Bio-markers (KL-6, SP-D and SP-A) in drug-induced pneumonitis Source: Eur Respir J 2002; 20: Suppl. 38, 59s Year: 2002 Differences in the immunolocalization of surfactant protein (SP)-A, SP-D and KL-6 in pulmonary alveolar proteinosis Source: Annual Congress 2008 - Miscellaneous aspects of interstitial lung disease Year: 2008 PP231 – Released mediators in ex vivo 3D-model of lung fibrosis correspond to elevated serum biomarkers in IPF Source: ERS Lung Science Conference 2021 Year: 2021 Released mediators in ex vivo 3D-model of lung fibrosis correspond to elevated serum biomarkers in IPF Source: Virtual Congress 2021 – Genetics and translational aspects of idiopathic pulmonary fibrosis Year: 2021 Elevated serum IL-8: a biomarker indicating exacerbation-prone COPD Source: International Congress 2017 – COPD biomarkers Year: 2017 High level of serum SP-D with normal range of KL-6 predicts a good prognosis of patients with fibrotic changes on HRCT Source: Annual Congress 2010 - Biomarkers in diffuse parenchymal lung disease Year: 2010 KL-6 is a useful serum biomarker for early detection of interstitial lung disease Source: Annual Congress 2012 - Diffuse parenchymal lung disease pathogenesis, biomarkers, therapy and new entities Year: 2012 PP102 – A serum biomarker reflecting human neutrophil elastase degraded calprotectin is elevated in COPD and IPF Source: ERS Lung Science Conference 2021 Year: 2021 The Gender-Age-Physiology (GAP) Index enhanced with KL-6 serum level for predicting disease progression in interstitial lung diseases (ILD). Source: Virtual Congress 2020 – Predictive markers of progression in connective tissue disease-associated interstitial lung disease and hypersensitivity pneumonitis Year: 2020 CHIT1 is a novel therapeutic target in idiopathic pulmonary fibrosis (IPF): anti-fibrotic efficacy of OATD-01, a potent and selective chitinase inhibitor in the mouse model of pulmonary fibrosis Source: International Congress 2018 – Progress in basic and translational research on idiopathic interstitial pneumonias Year: 2018